| Officer | Age | In this role | Joined | Pay | Source |
|---|---|---|---|---|---|
|
Johan (Thijs) Spoor
Also a director
Chief Executive Officer, Director
|
54 |
Since 2023
3 years
|
Not stated | Not reported | |
|
Joel Sendek
Chief Financial Officer, Principal Financial Officer
|
59 |
Since 2025
1 year
|
Not stated | Not reported | |
|
Markus Puhlmann
Chief Medical Officer
|
60 |
Since 2023
3 years
|
Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Sale of 5,634,235 Company common shares to Lantheus at $3.70 per share under the Lantheus Investment Agreement
Company acquired certain assets and associated sub-lease of Progenics' Somerset, New Jersey facility from Progenics, an affiliate of Lantheus, under the Progenics APA
Option granted to Lantheus for an exclusive option to negotiate a license to [212Pb]VMT-α-NET, in consideration of a one-time payment to the Company
Lantheus purchased 6,043,103 shares of common stock in the March 2024 Private Placement
License and access agreement giving Perspective access to dedicated and shared space at the Somerset Office
Loading...
